Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
CNY 7.6
(-1.3%)
CNY 7.6
(-1.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 809.99 Million CNY | -5.17% |
| 2022 | 854.18 Million CNY | 46.11% |
| 2021 | 584.64 Million CNY | 129.44% |
| 2020 | 254.8 Million CNY | 5.75% |
| 2019 | 240.95 Million CNY | 17.9% |
| 2018 | 204.37 Million CNY | 15.7% |
| 2017 | 176.64 Million CNY | -12.88% |
| 2016 | 202.75 Million CNY | -5.17% |
| 2015 | 213.81 Million CNY | 17.54% |
| 2014 | 181.9 Million CNY | 24.7% |
| 2013 | 145.87 Million CNY | 30.0% |
| 2012 | 112.21 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 625.52 Million CNY | -19.93% |
| 2024 Q3 | 723.56 Million CNY | 15.67% |
| 2024 Q1 | 781.23 Million CNY | -3.55% |
| 2023 Q2 | 918.01 Million CNY | 5.06% |
| 2023 Q1 | 873.76 Million CNY | 2.29% |
| 2023 Q3 | 860.24 Million CNY | -6.29% |
| 2023 FY | 809.99 Million CNY | -5.17% |
| 2023 Q4 | 809.99 Million CNY | -5.84% |
| 2022 Q4 | 854.18 Million CNY | 2.22% |
| 2022 Q3 | 835.62 Million CNY | 7.36% |
| 2022 FY | 854.18 Million CNY | 46.11% |
| 2022 Q1 | 615.78 Million CNY | 5.33% |
| 2022 Q2 | 778.35 Million CNY | 26.4% |
| 2021 FY | 584.64 Million CNY | 129.44% |
| 2021 Q3 | 454.04 Million CNY | 30.68% |
| 2021 Q1 | 211.49 Million CNY | -17.0% |
| 2021 Q2 | 347.43 Million CNY | 64.27% |
| 2021 Q4 | 584.64 Million CNY | 28.76% |
| 2020 Q1 | 187.8 Million CNY | -22.06% |
| 2020 FY | 254.8 Million CNY | 5.75% |
| 2020 Q2 | 208.28 Million CNY | 10.9% |
| 2020 Q3 | 214 Million CNY | 2.75% |
| 2020 Q4 | 254.8 Million CNY | 19.06% |
| 2019 Q3 | 204.41 Million CNY | 41.97% |
| 2019 FY | 240.95 Million CNY | 17.9% |
| 2019 Q1 | 212.63 Million CNY | 4.04% |
| 2019 Q4 | 240.95 Million CNY | 17.88% |
| 2019 Q2 | 143.98 Million CNY | -32.28% |
| 2018 Q2 | 188.8 Million CNY | 7.18% |
| 2018 FY | 204.37 Million CNY | 15.7% |
| 2018 Q1 | 176.15 Million CNY | -0.28% |
| 2018 Q4 | 204.37 Million CNY | 2.3% |
| 2018 Q3 | 199.78 Million CNY | 5.82% |
| 2017 Q4 | 176.64 Million CNY | 23.81% |
| 2017 FY | 176.64 Million CNY | -12.88% |
| 2017 Q1 | 212.19 Million CNY | 4.65% |
| 2017 Q2 | 160.39 Million CNY | -24.41% |
| 2017 Q3 | 142.67 Million CNY | -11.05% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 202.75 Million CNY | -5.17% |
| 2016 Q4 | 202.75 Million CNY | 0.0% |
| 2015 Q1 | 157.26 Million CNY | 0.0% |
| 2015 FY | 213.81 Million CNY | 17.54% |
| 2014 FY | 181.9 Million CNY | 24.7% |
| 2013 FY | 145.87 Million CNY | 30.0% |
| 2012 FY | 112.21 Million CNY | 0.0% |